A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and effectiveness of 131I-TM601 in the treatment of adult patients with progressive and/or recurrent malignant melanoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part Sarcoma Metastatic Alveolar Soft Part Sarcoma Locally Advanced Non Small Cell Lung Cancer +7 more

RECRUITING PHASE1

A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma

NCT00272415

Melanoma

TERMINATED PHASE1

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

NCT02196181

Stage III Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Melanoma

ACTIVE_NOT_RECRUITING PHASE2

Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

NCT00568451

Melanoma (Skin)

TERMINATED PHASE2

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

NCT01851408

Melanoma Recurrent Melanoma Stage III Melanoma +1 more

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, Phase 1/2 study evaluating the use of multiple intravenous doses of 131I-TM601 in adults patients with progressive and/or recurrent malignant melanoma (Stage IIIc or IV) with measurable disease who have failed first line/standard therapy.

The study will be conducted in 2 phases. During the first, Dose Escalation Phase, eligible patients wil be assigned in groups of 3-6 (depending upon the treatment response seen at each dose) to dose cohorts of between 2-5 weekly IV doses of 131I-TM601. Escalation to the next highest dose during the Dose Escalation Phase will be dependent upon demonstrated tolerance in the previous dosing group. In the second, Efficacy Phase, all patients will be treated with the Maximum Tolerated Dose determined in the Dose Escalation Phase.

Prior to initiating treatment, all patients will be administered a single imaging dose of 131I-TM601, IV, as an Imaging Dose to evaluate tumor uptake. Only patients demonstrating tumor uptake will remain on the study.

Patients in both study phases will have safety parameters evaluated continuously throughout the study. Clinical response to 131I-TM601 will be assessed in each study patient at 28 days following the final study dose, and then at 2-month intervals, starting at 3 months following the first study dose (during the first year of follow-up), and finally at 3-month intervals thereafter until disease progression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma Malignant Melanoma Metastatic Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

131I-TM601

Intervention Type DRUG

After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

131I-TM601

After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

chlorotoxin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patient MUST:

1. Have signed and dated written informed consent.
2. Be aged ≥ 18 years old at time of informed consent.
3. Have histologically proven Stage IIIc or IV malignant melanoma with documented progression during or following the most recent prior melanoma therapy.
4. Have measurable disease, defined as lesions that can be accurately measured in at least one dimension as \> 20 mm with conventional techniques (CT) or \> 10 mm with spiral CT scan or brain MRI.
5. Have failed at least 1 prior therapy for melanoma or refused first-line, standard therapy.
6. Have an ECOG performance status of 0 - 1.
7. Have a life expectancy, based on the Investigator's judgment, of \> 3 months.
8. On screening ECG, have a QTc interval of \< 450 ms.
9. If taking steroids, be on a dose that is stable for at least 5 days prior to the Imaging Dose.
10. Have recovered from the toxicity of all previous therapy prior to enrollment. If the patient has undergone recent major surgery, an interval of at least 3 weeks must have elapsed between the surgery and the date of the Imaging Dose.
11. Have acceptable laboratory results as follows:

1. Hemoglobin ≥ 9g/dL
2. ANC ≥ 1,500 mm3
3. Platelet count ≥ 150,000 mm3
4. PT \<1.5 ULN
5. PTT \< 1.5 ULN
6. Total Bilirubin \< 2.0 mg/dL
7. AST/ALT \< or = 5 ULN
8. Serum Creatinine \< or = 2 mg/dL
12. Have a negative serum pregnancy test within 14 days of study drug administration, if female and of child bearing potential.
13. Agree to use an effective form of contraception to avoid pregnancy, if fertile (applicable to both male and female patients).
14. Agree to refrain from nursing, if female.
15. Be able to comply with treatment plan, study procedures, and follow-up examinations.

If enrolled in the single site Sub-Study, patient MUST:
16. Have at least one accessible biopsy site and a second measurable target site per RECIST criteria.
17. Agree to pre-infusion and post-infusion biopsies of tumor lesions.

Exclusion Criteria

Patient May Not:

1. Have a serious concurrent infection or medical illness which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety. Examples of medical illnesses include, but are not limited to, the following: uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, known history of HIV, Hepatitis B or Hepatitis C infection, or psychiatric illness/social situation which would limit compliance with study requirements.
2. Have CNS metastases, unless, in the PI's judgment, the CNS involvement is stable and not likely to require further palliative therapy to the CNS during the course of the treatment protocol. If previous treatment has included radiotherapy, CNS disease should be stable at least 6 weeks from receipt of previous radiotherapy.
3. Have a prior malignancy with less than 3-year disease-free interval, except for adequately treated basal cell or squamous cell carcinoma of the skin, or in situ cancer of the cervix.
4. Have received radiation treatments \< 6 weeks prior to first study drug administration (Imaging Dose).
5. Have previously received radiation to ≥ 25% red bone marrow.
6. Have received any cytotoxic chemotherapy, hormonal therapy, or immunotherapy, whether conventional or investigational, \< 4 weeks prior to receiving the first study drug (Imaging Dose) administration in this study (6 weeks for mitomycin-C or nitrosoureas).
7. Have a history of pulmonary embolism within 1 year or deep venous thrombosis within six months of study enrollment.
8. Current or recent history of high-dose aspirin, warfarin, or heparin use (Aspirin \< or = 81 mg/day, low-dose warfarin \< 1 mg/day, or low-dose heparin for IV catheter patency is allowed).
9. Received investigational agents within 4 weeks prior to receiving the first study drug (Imaging Dose) administration in this study.
10. Have a history of allergic reactions attributed to compounds of similar chemical or biological composition to 131I-TM601 e.g. iodine or iodine-containing drugs.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No